News and Views on the SSRI Group of Drugs


  • STOP the Lies: Join the Cause: Click pic below

  • Enter your email address to subscribe to this blog and receive notifications of new posts by email.

    Join 7 other followers

  • Monthly Archive showing # of posts

  • Advertisements

Posts Tagged ‘GlaxoSmithKline’

2011 SSRI Related Deaths

Posted by shutah on February 20, 2011

It’s Sunday, 20 February 2011

51 days into the year

43 incidents listed already


SSRI Related Deaths 2011


Does anyone care?









Posted in GlaxoSmithKline, GSK, MHRA, SSRIs | Tagged: , , , , , , , , , , , , | Leave a Comment »

Crusader’s highly deserved recognition

Posted by shutah on February 19, 2011

Surely, one of the proudest moment’s in Bob Fiddaman’s quest for justice in the eternal fight against SSRI’s .

As Bob writes in his blog “What could piss off GlaxoSmithKline more than Bob Fiddaman getting an award for basically highlighting their dark history?”

Way to go Fiddy!!!!!!

[Click the pic to read the full story]

Posted in Blogroll, Depression, GlaxoSmithKline, GSK, Health, Paroxetine, Paxil, Seroxat, SSRIs | Tagged: , , , , , , | 1 Comment »

GSK gives in – Last-minute deal in Avandia suit

Posted by shutah on January 31, 2011

A federal court in Philadelphia was all set to hear a liability lawsuit against GlaxoSmithKline today, but an 11th-hour settlement took that case right off the docket. GSK made a deal with the family of Avandia patient James Burford to resolve claims that the diabetes drug caused his fatal heart attack. GSK recently took a $3.5 billion charge for legal expenses, including new Avandia litigation filed in the U.S.

The settlement lets GSK avoid the risk of a jury trial, Matrix Corporate Capital analyst Navid Malik told Bloomberg. Investors had worried that a trial “could lead to substantial punitive damages,” Malik said. “GSK needs to successfully settle as many of these cases as possible.”

Two other suits brought by the same plaintiff attorneys were also settled. “GSK has resolved the Burford case scheduled for trial today in the U.S. District Court in Philadelphia, and all cases represented by attorneys Joseph Zonies and Thomas Cartmell,” GSK said in a statement, which also emphasizes that, “GSK continues to stand behind the safety and efficacy of Avandia when used appropriately and according to its label.”

Avandia’s safety, particularly its potential link to heart attack risks, has been under debate for several years, and GSK has already resolved some 10,000 liability suits with a $460 million settlement. In September, European regulators banned Avandia, saying its risks outweighed its benefits. The FDA stopped short of withdrawing the drug, but sharply restricted its use, and GSK agreed to stop promoting it. About 2,000 more lawsuits remain outstanding.

This SUCKS!!!  Not for the Claimants, I’m thrilled for them.  But GSK have ‘settled’ the case, thereby allowing them to walk away from their responsibilities by not having to testify in Court.

Their statement … “GSK continues to stand behind the safety and efficacy of Avandia ….” shows them to be lily-livered, cold-hearted bureaucrats with a seemingly bottomless well of money to throw about.  I’ll bet GSK doesn’t have the balls to ‘fess up to their errors when it comes to the SSRI drugs they ‘peddle’ around the World!!!  Boo, Hiss GSK!!!!

Posted in GlaxoSmithKline | Tagged: , , , , , , , | Leave a Comment »

Glaxo Avandia Settlement [latest news]

Posted by shutah on January 25, 2011

Oh Dear!!  GSK in the spotlight a lot this week.

Reports said Monday thatGlaxoSmithKline is bound to face a multi-district litigation amounting to an estimated $3.4 billion against its anti-diabetes drug, Avandia.

According to the reports, a number of pending litigations against Avandia, an oral anti-diabetic agent which acts primarily by increasing insulin sensitivity, are filed in different states of America. Federal courts’ records show that more than 50,000 complaints were reported against the adverse effect of Avandia.

In 2010, Glaxo already settled an approximated 10,000 Avandia cases with an average settlement of $460 million. On Monday, another lawsuit was heard in the US District Court for the Eastern District of Pennslyvania. The lawsuit involves a claim filed by the relatives of James Buford, a diabetic patient who had been taking Avandia for 15 months, after the latter died of heart attack.

The incident proves a meta-analysis of 42 clinical studies, saying that daily intake of the anti-diabetes drug can relatively increase the risk of myocardial ischemic attack such as angina pectoris and myocardial infarction. Buford’slawyer argued that approximately three weeks after Buford started takingAvandia, the patient suffered symptoms that suggested a mild heart attack. Earlier this month, Glaxo announced that it was reserving $ 3.4 billion to cover the contingency loss brought by the Avandia lawsuits.

Meanwhile, a second trial against Avandia is scheduled to begin on March 28 this year, which involves a patient who allegedly used the drug and suffered congestive heart failure from Avandia. Experts said that Avandia has caused 60,000 and 200,000 heart attacks and deaths due to cardiovascular problems in the United States from 1999 to 2006. Glaxo is currently under investigation by the US Department of Justice and several other state lawyers for potential fraud.

Wouldn’t it be great if the UK ‘Justice Department’ investigated Glaxo on behalf of all those, past and present, who suffer at the hands of their drug Seroxat/Paxil?

Posted in SSRIs | Tagged: , , , , , , , , | 2 Comments »

GSK pulls ED ads to help rehab its image

Posted by shutah on January 25, 2011

Whoopy bloody dooooo!!!  Not before time that they [GSK] started to take some responsibility for their actions (inactions)!!!!

GlaxoSmithKline is pulling ads for its erectile dysfunction drug Levitra. And it’s making a big show of that choice; North American President Deirdre Connelly said it’s part of the company’s new push to be more transparent and operate with integrity. “When we walk into your home through television, we have to do it in a respectful way,” Connelly said to the Wall Street Journal.

Basically, Connelly lumped the Levitra ad move in with GSK’s ongoing campaign to break with the past, which has been sullied by off-label marketing allegations, whistleblower suits, safety questions and quality problems. And when GSK took a $3.4 billion charge for legal liabilities–including lawsuits over the recently restricted diabetes drug Avandia and a potential Justice Department settlement in an off-label marketing probe–some industry observers pegged the move as an attempt to start fresh. That charge came on top of last year’s $750 million manufacturing settlement, another longtime battle put to rest.

The company has done some other things aimed at the integrity target. It set up public databases of its payments to doctors and medical schools, and its educational and charitable grants. It changed the rules on funding continuing medical education. It just got rid of sales-related bonuses for reps, hoping that a broader job-performance focus will play well with patients and doctors–and perhaps to offset suspicions that could arise with an off-label marketing settlement. GSK has also cut prices in the developing world to give poor people easier access to medicines, a move CEO Andrew Witty has touted repeatedly. The message is clear–we’re doing business differently now.

Posted in GlaxoSmithKline, GSK | Tagged: , , , , , , , | Leave a Comment »